BofA analyst Travis Steed raised the firm’s price target on Beta Bionics (BBNX) to $33 from $30 and keeps a Buy rating on the shares as the firm moves the valuation year out one year to reflect the calendar change while highlighting its medtech picks for 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX: